Hemolytic-Uremic Syndrome clinical trials at University of California Health
4 research studies open to eligible people
Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
open to eligible people ages up to 17 years
This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
at UC Davis
Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 12 years and up
This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.
at UC Davis UC Irvine UCSF
Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
open to eligible people ages 18 years and up
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
at UCLA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
open to eligible people ages 9 months to 21 years
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).
at UC Davis UCSD
Our lead scientists for Hemolytic-Uremic Syndrome research studies include Sarah Tomassetti.
Last updated: